Cipla Share Surges Over 4%; Leadership Revamp, and ESOP Grant Bolster Bullish Case

Mumbai, June 22: Shares of Cipla (NSE: CIPLA) opened Monday’s session firmly in positive territory at ₹1,372.00 against a previous close of ₹1,351.80, and the stock barely paused for breath after that. From the open, buyers drove the counter higher in a near-unbroken ascent, with the price climbing steadily through the morning to touch a session high of ₹1,409.00.  

The rally showed no sign of fatigue as the day progressed — by the time the clock passed noon, Cipla was trading at ₹1,407.10, up ₹55.30 or 4.09% from the previous close. The VWAP of ₹1,394.09 indicates that the bulk of the day’s volume traded well above the opening price, reflecting sustained accumulation rather than a brief spike. The order book underscored the bullish tilt, with 52.49% buy orders (1,99,888 shares) against 47.51% sell orders (1,80,957 shares) — a decisive buyer majority that points to continued demand even at elevated levels. 

Weekly Trend 

The weekly chart tells a story of a stock that spent the past five sessions under steady selling pressure — and then snapped back with authority on Monday. Cipla opened the week of June 15 around ₹1,381, but closed lower on each successive day, sliding through ₹1,374 on June 16, dipping to a weekly low near ₹1,351 on June 17, and stabilising around ₹1,356–58 through June 18–19. The Friday close of ₹1,351.80 was the weakest print of the week, raising questions among short-term traders about near-term support. Monday’s sharp reversal — with the stock surging above ₹1,407 intraday — breaks that five-day downtrend decisively and suggests that the recent weakness attracted fresh institutional buying. The gap between the weekly low of roughly ₹1,351 and Monday’s high of ₹1,409 represents a recovery of over 4% in a single session, a move that technically reclaims all of last week’s losses and more. 

Source: NSE India — Cipla weekly price chart, June 15–19, 2026 

Three Positive Developments Underpin the Rally 

The US Food and Drug Administration classified Cipla’s Goa manufacturing facility as Voluntary Action Indicated (VAI) on June 10, 2026, following an inspection of the plant in April this year. A VAI classification means the USFDA will not take or recommend any regulatory or enforcement action, as the observations noted during the inspection did not meet the threshold for intervention. The clean outcome removes a key regulatory overhang for Cipla’s US business, which is a significant revenue contributor for the company. 

Cipla on last Tuesday (June 16) informed the stock exchanges that its board has approved the appointment of Shivam Puri — currently Managing Director and CEO of Cipla Health Limited, a wholly owned subsidiary — as Chief Executive Officer of its One India Business, with effect from July 1, 2026. Puri, an IIT-BHU and IIM Lucknow alumnus with over 23 years of FMCG and healthcare leadership experience, will also join Cipla’s Management Council and be designated as senior management personnel of the company. The appointment, made on a full-time basis, signals Cipla’s intent to sharpen domestic market focus under a leader who has already transformed Cipla Health from a startup into one of India’s leading wellness goods companies over the past seven years. 

The same June 16 exchange filing also disclosed a fresh grant of employee stock options and appreciation rights under two long-standing schemes. Under the Cipla Employee Stock Option Scheme, the company granted 11,360 stock options at an exercise price of ₹2 per option, with a vesting period of two years from the grant date and an exercise window of five years from the vesting date. Under the Cipla Employee Stock Appreciation Rights Scheme 2021, 51,394 Employee Stock Appreciation Rights (ESARs) were granted at an exercise price of ₹2 per equity share, with a three-year graded vesting schedule and a five-year exercise period from the vesting date. The grants, made under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, are a standard retention and alignment tool — but their timing, alongside the Shivam Puri appointment, reinforces the message that Cipla is actively deepening management commitment as it positions for the next phase of domestic growth. 

Source

• https://www.nseindia.com/get-quote/equity/CIPLA/Cipla-Limited